Company · positioning
Alnylam PharmaceuticalsIncumbent
Positioned in 2 collision spaces.
2Collision spaces
Nanotechnology×Disease
69.1Index
Pioneer of GalNAc and LNP-mediated RNAi delivery; its platform is the clearest precedent for organ-targeted nanoparticle therapeutics against disease-causing gene products.
Open collisionTransgene×Nanotechnology
43.9Index
Pioneered clinical LNP delivery for nucleic acids (siRNA); their formulation IP and manufacturing scale are directly transferable to CRISPR transgene payloads.
Open collision